title: Rivaroxaban for the treatment of venous thromboembolism. A "real-life" perspective in 103 patients.
abstract: BACKGROUND
  Randomized clinical trials have demonstrated non-inferiority of rivaroxaban compared with vitamin K antagonists (VKAs) in the treatment of venous thromboembolism (VTE). Our objective was to analyze in real life, tolerance, recurrence, bleeding and adverse events of rivaroxaban in patients with acute symptomatic VTE.
  
  
  METHODS
  Open follow-up study of a cohort of patients aged 18 and over diagnosed with deep vein thrombosis (DVT) and/or pulmonary embolism (PE) treated with rivaroxaban from December 2011 to January 2014.
  
  
  RESULTS
  The total number of patients treated with rivaroxaban was 103. The mean age was 58+/-17 years. The most frequent co-morbidities were: hypertension (30.0%), dyslipidemia (23.3%) and respiratory disease (25.2%). The type of thromboembolic event treated was: DVT (64.1%), PE (18.4%), DVT+PE (17.5%). Of the rivaroxaban-treated patients, 30% did so from the initial anticoagulant therapy and the other 70% in long-term or extended anticoagulant therapy. The median time of treatment with rivaroxaban was 6 months [corrected]. There was one recurrence and no deaths occurred. Six patients had bleeding, one of which was severe.
  
  
  CONCLUSIONS
  Rivaroxaban provides a therapeutic alternative in a group of patients with VTE with advantages over VKAs, because of the convenience in dosing, lack of requirements for periodic monitoring and limited interaction with other drugs.
authors.affiliation: Medical Surgical Unit of Respiratory Diseases, Hospital Virgen del Rocío, CIBERES, Seville, Spain.
authors.forename: Luis
authors.initials: L
authors.lastname: Jara-Palomares
authors.affiliation: Medical Surgical Unit of Respiratory Diseases, Hospital Virgen del Rocío, CIBERES, Seville, Spain.
authors.forename: Raquel
authors.initials: R
authors.lastname: Sanchez-Oro-Gomez
authors.affiliation: Medical Surgical Unit of Respiratory Diseases, Hospital Virgen del Rocío, CIBERES, Seville, Spain.
authors.forename: Teresa
authors.initials: T
authors.lastname: Elias-Hernandez
authors.affiliation: Medical Surgical Unit of Respiratory Diseases, Hospital Virgen del Rocío, CIBERES, Seville, Spain.
authors.forename: Raquel
authors.initials: R
authors.lastname: Morillo-Guerrero
authors.affiliation: Medical Surgical Unit of Respiratory Diseases, Hospital Virgen del Rocío, CIBERES, Seville, Spain.
authors.forename: Marta
authors.initials: M
authors.lastname: Ferrer-Galvan
authors.affiliation: Medical Surgical Unit of Respiratory Diseases, Hospital Virgen del Rocío, CIBERES, Seville, Spain.
authors.forename: Maria Isabel
authors.initials: MI
authors.lastname: Asensio-Cruz
authors.affiliation: Medical Surgical Unit of Respiratory Diseases, Hospital Virgen del Rocío, CIBERES, Seville, Spain.
authors.forename: Emilia
authors.initials: E
authors.lastname: Barrot-Cortes
authors.affiliation: Medical Surgical Unit of Respiratory Diseases, Hospital Virgen del Rocío, CIBERES, Seville, Spain.
authors.forename: Remedios
authors.initials: R
authors.lastname: Otero-Candelera
mesh_terms: D000328:Adult; D000368:Aged; D065427:Factor Xa Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D018579:Patient Selection; D011655:Pulmonary Embolism / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D012008:Recurrence; D012307:Risk Factors; D000069552:Rivaroxaban / Q000009:adverse effects / Q000627:therapeutic use*; D013030:Spain; D013997:Time Factors; D016896:Treatment Outcome; D054556:Venous Thromboembolism / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D020246:Venous Thrombosis / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D065427:Factor Xa Inhibitors; D000069552:Rivaroxaban
keywords: Anticoagulants; Pulmonary embolism; Rivaroxaban; Venous thromboembolism; Venous thrombosis